Help understanding how to get the medicine you need
Genentech Access Solutions works with your doctor and health insurance company (and specialty pharmacy, if needed) to help you get your medicine.
If you are eligible, options to help you pay for Actemra may include*:
- Genentech Rheumatology co-pay cards
to independent co-pay assistance foundations
Genentech® Access to Care Foundation, or GATCF
*Patients must meet certain criteria.
The Genentech Rheumatology Co-pay Card Program
The Genentech Rheumatology Co-pay Card Program helps eligible
commercially insured patients pay
$5 per drug co-pay. The card is
valid for up to
$15,000 of co-pay assistance within
a 12-month period. This program helps pay for costs described as
"out of pocket", "co-pay" or "uncovered
expenses" for ACTEMRA only. Office visit costs are not
To find out if you are eligible for any of our programs, please use
the tool below or call 1-855-RA-COPAY (1-855-722-6729) to talk
with a specialist.
Genentech Rheumatology Co-pay Card Program
This program might be able to help reduce out-of-pocket expenses associated with your prescription.
Independent Co-pay Assistance Foundations
If you need help with medication co-pays, we can refer you to independent co-pay assistance foundations. Foundations have their own specific criteria.
The Genentech® Access to Care Foundation, or GATCF
GATCF helps qualified patients receive their medicine free of charge. To qualify for free medicine from GATCF, you need to meet specific criteria.
Genentech Rheumatology Co-pay Terms and Conditions
By using the Genentech Rheumatology Co-pay Card program, the patient acknowledges and confirms that at the time of usage, (s)he is currently eligible and meets the criteria set forth in the terms and conditions described.
This Co-pay Card is valid ONLY for patients with commercial (private or nongovernmental) insurance. It is not valid for patients who are government beneficiaries or whose medications are covered, in whole or in part, under Medicaid; Medicare Part A, B, C and/or D; TRICARE; CHAMPUS; Puerto Rico Government Health Insurance Plan or any other state or federal health care program. Patients who become government beneficiaries during their enrollment period will no longer be eligible for the program as of the date they become a government beneficiary.
The Genentech Rheumatology Co-pay Card program is not health insurance or a benefit plan. Distribution or use of the Co-pay Card does not obligate use or continuing use of any specific product or provider. Patient or guardian is responsible for reporting the receipt of all Genentech Rheumatology Co-pay Card program benefits or reimbursement received, to any insurer, health plan or other third party who pays for or reimburses any part of the prescription filled using the Genentech Rheumatology Co-pay Card program, as may be required.
The Co-pay Card is not valid for medications the patient receives for free or that are eligible to be reimbursed by private insurance plans or other health care or pharmaceutical assistance programs (such as: GATCF or any other charitable organization) that reimburse the patient in part or for the entire cost of his/her medication. Patient, guardian, pharmacist, prescriber and any other person using the Co-pay Card agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer.
The Co-pay Card will be accepted by participating pharmacies, physician offices or hospitals. To qualify for the benefits of the Genentech Rheumatology Co-pay Card program, the patient may be required to pay out-of-pocket expenses for each treatment. Once enrolled, the Genentech Rheumatology Co-pay Card program will not honor claims with date of service or medication dispensing that precede Genentech Rheumatology Co-pay Card program enrollment by more than 120 days. This Co-pay Card is only available with a valid prescription and cannot be combined with any other rebate/coupon, free trial or similar offer for the specified prescription. Use of this Co-pay Card must be consistent with all relevant health insurance requirements and payer agreements. Participating patients, pharmacies, physician offices and hospitals are obligated to inform third-party payers about the use of the Co-pay Card as provided for under the applicable insurance or as otherwise required by contract or law. The Co-pay Card may not be sold, purchased, traded or offered for sale, purchase or trade. The Co-pay Card is limited to 1 per person during this offering period and is not transferable. The Genentech Rheumatology Co-pay Card program expires within 12 months from enrollment. The Genentech Rheumatology Co-pay Card program is not valid where prohibited by law. For Massachusetts’ residents, the Co-pay Card is not valid for any prescription drug that has an AB rated generic equivalent as determined by the United States Food and Drug Administration. For Massachusetts’ residents, the Genentech Rheumatology Co-pay Card program shall expire on or before July 1, 2017.
The patient or their guardian must be 18 years or older to receive Genentech Rheumatology Co-pay Card program assistance. The Genentech Rheumatology Co-pay Card program is: (1) void if the card is reproduced; (2) void where prohibited by law; (3) only valid in the United States and Puerto Rico; and (4) only valid for Genentech products. Health care providers may not advertise or otherwise use the program as a means of promoting their services or Genentech’s products to patients. Genentech, Inc. reserves the right to rescind, revoke or amend the program without notice at any time.
The Access Solutions logo is a registered trademark of Genentech, Inc.
The ACTEMRA Prepaid MasterCard® is issued by The Bancorp Bank pursuant to license by MasterCard International Incorporated. The Bancorp Bank; Member FDIC. This card may not be used everywhere Debit MasterCard® is accepted. No cash or ATM access. MasterCard® is a registered trademark of MasterCard International Incorporated.
Before reading more, please see the Important Side Effect Information for ACTEMRA
This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
INDICATION AND IMPORTANT SIDE EFFECT INFORMATION
What is ACTEMRA?
ACTEMRA is a prescription medicine that targets the interleukin-6 (IL-6) signaling pathway. ACTEMRA is used to treat:
- Adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a Disease Modifying Anti-Rheumatic Drug (DMARD) has been used and did not work well.
- Adults with giant cell arteritis (GCA).
- People with active PJIA ages 2 and above.
- People with active SJIA ages 2 and above.
ACTEMRA is not approved for subcutaneous use in people with PJIA or SJIA.
It is not known if ACTEMRA is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.
What is the most important information I should know about ACTEMRA?
ACTEMRA can cause serious side effects including:
1. Serious Infections.
ACTEMRA is a medicine that affects your immune system. ACTEMRA can lower the ability of your immune system to fight infections. Some people have serious infections while taking ACTEMRA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.
Your healthcare provider should test you for TB before starting ACTEMRA.
- Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with ACTEMRA.
You should not start taking ACTEMRA if you have any kind of infection unless your healthcare provider says it is okay.
Before starting ACTEMRA, tell your healthcare provider if you:
- think you have an infection or have symptoms of an infection, with or without a fever, such as:
- sweating or chills
- shortness of breath
- warm, red, or painful skin or sores on your body
- feel very tired
- muscle aches
- blood in phlegm
- diarrhea or stomach pain
- weight loss
- burning when you urinate or urinating more often than normal
- are being treated for an infection
- get a lot of infections or have infections that keep coming back
- have diabetes, HIV, or a weak immune system. People with these conditions have a higher chance for infections.
- have TB, or have been in close contact with someone with TB
- live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections (histoplasmosis, coccidiomycosis, or blastomycosis). These infections may happen or become more severe if you use ACTEMRA. Ask your healthcare provider, if you do not know if you have lived in an area where these infections are common.
- have or have had hepatitis B
After starting ACTEMRA, call your healthcare provider right away if you have any symptoms of an infection. ACTEMRA can make you more likely to get infections or make worse any infection that you have.
2. Tears (perforation) of the stomach or intestines.
- Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking ACTEMRA get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
- Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away, and a change in your bowel habits.
3. Changes in certain laboratory test results.
Your healthcare provider should do blood tests before you start receiving ACTEMRA. If you have rheumatoid arthritis (RA) or giant cell arteritis (GCA) your healthcare provider should do blood tests 4 to 8 weeks after you start receiving ACTEMRA and then every 3 months after that. If you have polyarticular juvenile idiopathic arthritis (PJIA) you will have blood tests done every 4 to 8 weeks during treatment. If you have systemic juvenile idiopathic arthritis (SJIA) you will have blood tests done every 2 to 4 weeks during treatment. These blood tests are to check for the following side effects of ACTEMRA:
- low neutrophil count. Neutrophils are white blood cells that help the body fight off bacterial infections.
- low platelet count. Platelets are blood cells that help with blood clotting and stop bleeding.
- increase in certain liver function tests.
- increase in blood cholesterol levels. You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start receiving ACTEMRA, and then every 6 months after that.
You should not receive ACTEMRA if your neutrophil or platelet counts are too low or your liver function tests are too high.
Your healthcare provider may stop your ACTEMRA treatment for a period of time or change your dose of medicine if needed because of changes in these blood test results.
ACTEMRA may increase your risk of certain cancers by changing the way your immune system works. Tell your healthcare provider if you have ever had any type of cancer.
See “What are the possible side effects with ACTEMRA?” for more information about side effects.
Who should not take ACTEMRA?
Do not take ACTEMRA: if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA. See the end of this Medication Guide for a complete list of ingredients in ACTEMRA.
What should I tell my healthcare provider before receiving ACTEMRA?
Before you receive ACTEMRA, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection. See “What is the most important information I should know about ACTEMRA?”
- have liver problems.
- have any stomach-area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines.
- have had a reaction to tocilizumab or any of the ingredients in ACTEMRA before.
- have or had a condition that affects your nervous system, such as multiple sclerosis.
- have recently received or are scheduled to receive a vaccine.
- All vaccines should be brought up-to-date before starting ACTEMRA.
- People who take ACTEMRA should not receive live vaccines.
- People taking ACTEMRA can receive non-live vaccines.
- plan to have surgery or a medical procedure.
- have any other medical conditions.
- plan to become pregnant or are pregnant. It is not known if ACTEMRA will harm your unborn baby.
Pregnancy Registry: Genentech has a registry for pregnant women who take ACTEMRA. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking ACTEMRA, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.
- plan to breastfeed or are breastfeeding. You and your healthcare provider should decide if you will take ACTEMRA or breastfeed. You should not do both.
Tell your healthcare provider about all of the medicines you take, including prescription, over-the-counter medicines, vitamins and herbal supplements. ACTEMRA and other medicines may affect each other causing side effects.
Especially tell your healthcare provider if you take:
- any other medicines to treat your RA. You should not take etanercept (Enbrel®), adalimumab (Humira®), infliximab (Remicade®), rituximab (Rituxan®), abatacept (Orencia®), anakinra (Kineret®), certolizumab (Cimzia®), or golimumab (Simponi®), while you are taking ACTEMRA. Taking ACTEMRA with these medicines may increase your risk of infection.
- medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.
Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I receive ACTEMRA?
Into a vein (IV or intravenous infusion) for Rheumatoid Arthritis, PJIA, or SJIA:
- If your healthcare provider prescribes ACTEMRA as an IV infusion, you will receive ACTEMRA from a healthcare provider through a needle placed in a vein in your arm. The infusion will take about 1 hour to give you the full dose of medicine.
- For rheumatoid arthritis or PJIA you will receive a dose of ACTEMRA about every 4 weeks.
- For SJIA you will receive a dose of ACTEMRA about every 2 weeks.
- While taking ACTEMRA, you may continue to use other medicines that help treat your rheumatoid arthritis, PJIA, or SJIA such as methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs) and prescription steroids, as instructed by your healthcare provider.
- Keep all of your follow-up appointments and get your blood tests as ordered by your healthcare provider.
Under the skin (SC or subcutaneous injection) for Rheumatoid Arthritis or Giant Cell Arteritis:
- See the Instructions for Use at the end of this Medication Guide for instructions about the right way to prepare and give your ACTEMRA injections at home.
- ACTEMRA is available as a single-use Prefilled Syringe.
- You may also receive ACTEMRA as injection under your skin (subcutaneous). If your healthcare provider decides that you or a caregiver can give your injections of ACTEMRA at home, you or your caregiver should receive training on the right way to prepare and inject ACTEMRA. Do not try to inject ACTEMRA until you have been shown the right way to give the injections by your healthcare provider.
- Your healthcare provider will tell you how much ACTEMRA to use and when to use it.
What are the possible side effects with ACTEMRA?
ACTEMRA can cause serious side effects, including:
- See “What is the most important information I should know about ACTEMRA?”
- Hepatitis B infection in people who carry the virus in their blood. If you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus may become active while you use ACTEMRA. Your doctor may do blood tests before you start treatment with ACTEMRA and while you are using ACTEMRA. Tell your healthcare provider if you have any of the following symptoms of a possible hepatitis B infection:
- feel very tired
- dark urine
- skin or eyes look yellow
- clay-colored bowel movements
- stomach discomfort
- skin rash
- little or no appetite
- muscle aches
- Serious Allergic Reactions. Serious allergic reactions, including death, can happen with ACTEMRA. These reactions can happen with any infusion or injection of ACTEMRA, even if they did not occur with an earlier infusion or injection. Tell your healthcare provider before your next dose if you had hives, rash or flushing after your injection. Seek medical attention right away if you have any of the following signs of a serious allergic reaction:
- shortness of breath or trouble breathing
- swelling of the lips, tongue, or face
- chest pain
- feeling dizzy or faint
- moderate or severe abdominal pain or vomiting
- Nervous system problems. While rare, Multiple Sclerosis has been diagnosed in people who take ACTEMRA. It is not known what effect ACTEMRA may have on some nervous system disorders.
The most common side effects of ACTEMRA include:
- upper respiratory tract infections (common cold, sinus infections)
- increased blood pressure (hypertension)
- injection site reactions
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Genentech at 1-888-835-2555.
General information about the safe and effective use of ACTEMRA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not give ACTEMRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ACTEMRA that is written for health professionals.
For more information, call 1-800-ACTEMRA.
What are the ingredients in ACTEMRA?
Active ingredient: tocilizumab
Inactive ingredients of Intravenous ACTEMRA: sucrose, polysorbate 80, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate.
Inactive ingredients of Subcutaneous ACTEMRA: L-arginine, L-arginine hydrochloride, L-methionine, L-histidine, L-histidine hydrochloride monohydrate.